title: Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases.
abstract: Anti-oxidative enzymes protect living bodies from various oxidative stresses. In the systemic autoimmune diseases, autoantibodies to oxidized molecules and to anti-oxidative enzymes have been reported. To promote understanding of the relationships between autoimmunity and oxidative stress, we here investigate whether autoimmunity to the anti-oxidative peroxiredoxin (Prxs) enzymes exists in patients with systemic autoimmune diseases. Specifically, we detected autoantibodies to recombinant Prx I and Prx IV respectively by ELISA and western blotting. Next, clinical parameters were compared between the anti-Prx I or IV-positive and-negative patients. We found that 33% of the 92 patients with autoimmune diseases tested possessed autoantibodies to Prx I (57% in systemic lupus erythematosus (SLE), 19% in rheumatoid arthritis (RA), 5% in Behçet disease, and 46% in primary vasculitis syndrome). In contrast, autoantibodies to Prx IV were detected in only 17% of the same patients. No significant correlation was found between occurrence of the two autoantibodies. Clinically, possession of anti-Prx I autoantibodies correlated with lower serum levels of CH50, C3, and C4. Taken together, our data demonstrate the existence of autoantibodies to Prxs for the first time. The autoantibodies to Prx I may be involved in the pathophysiology of systemic autoimmune diseases such as SLE and vasculitis.
authors.affiliation: Department of Bioregulation & Proteomics, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
authors.forename: Rie
authors.initials: R
authors.lastname: Karasawa
authors.forename: Shoichi
authors.initials: S
authors.lastname: Ozaki
authors.forename: Kusuki
authors.initials: K
authors.lastname: Nishioka
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kato
mesh_terms: D001172:Arthritis, Rheumatoid / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D001327:Autoimmune Diseases / Q000276:immunology*; D001528:Behcet Syndrome / Q000276:immunology; D015153:Blotting, Western; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D015941:Complement Hemolytic Activity Assay; D004797:Enzyme-Linked Immunosorbent Assay; D006360:Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology*; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000276:immunology; D010544:Peroxidases / Q000276:immunology*; D061105:Peroxiredoxin III; D054464:Peroxiredoxins
chemical_list: D001323:Autoantibodies; D003176:Complement C3; D003181:Complement C4; D006360:Heat-Shock Proteins; D009363:Neoplasm Proteins; D010544:Peroxidases; C516115:PRDX3 protein, human; D061105:Peroxiredoxin III; D054464:Peroxiredoxins; C021567:methylamine dehydrogenase; D000587:Oxidoreductases Acting on CH-NH Group Donors